Radiopharm Theranostics (RADX) names Bruce Michael Goodwin as director insider on Form 3
Rhea-AI Filing Summary
Radiopharm Theranostics Ltd filed an initial insider report for director Bruce Michael Goodwin. This Form 3 identifies him as a director but does not list any reportable transactions or derivative positions. The filing serves to register his status as an insider for future ownership reporting.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Radiopharm Theranostics (RADX) Form 3 for Bruce Michael Goodwin show?
The Form 3 identifies Bruce Michael Goodwin as a director of Radiopharm Theranostics Ltd. It reports no transactions, no derivative positions, and serves as his initial insider ownership registration with U.S. securities regulators for future reporting obligations.
Does the RADX Form 3 disclose any derivative securities for Bruce Michael Goodwin?
No derivative securities are disclosed. The derivative section is empty and the summary shows 0 derivative transactions. This means there are no options, warrants, or similar instruments reported for Goodwin in this initial insider filing.
What is the purpose of this Radiopharm Theranostics (RADX) Form 3 filing?
This Form 3 serves as an initial statement of beneficial ownership for director Bruce Michael Goodwin. It formally records his insider status so that any future trades or holdings in Radiopharm Theranostics securities can be reported on subsequent SEC forms.
Does the RADX Form 3 indicate whether Bruce Michael Goodwin is a 10% owner?
No, the filing indicates he is not a 10% owner. The metadata flags him as a director only, with the ten percent owner field set to 0, clarifying that his insider status is based on board membership rather than ownership size.